2 citations
,
October 2019 in “Nanomedicine” This commentary discusses current challenges and future opportunities in pharmaceutical care for organ transplant recipients, focusing on immunosuppressive strategies, their complexities, and potential advancements like nanoimmunotherapy, but reports no new clinical results.
822 citations
,
January 2021 in “Genome biology” This study presents a new method called scMC that effectively distinguishes biological from technical variation in single-cell genomics datasets, demonstrating its ability to accurately align and detect biological signals across various experiments.
November 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” This study identified five FDA-approved drugs, including cepharantine and clofazimine, as potential COVID-19 therapies through in silico and in vitro screening targeting viral entry mechanisms.
54 citations
,
March 1991 in “Proceedings of the National Academy of Sciences” This study describes a gel-supported in vitro system for culturing skin samples that may effectively replace animal systems for toxicity testing, showing high correlation with in vivo skin toxicity measurements.
29 citations
,
February 2022 in “Frontiers in Cell and Developmental Biology” This review discusses strategies to improve CRISPR/Cas systems by addressing limitations like off-target effects and delivery inefficiencies, offering practical guidance and highlighting future applications, but reports no new research findings.
April 2024 in “JMR. Journal of molecular recognition/Journal of molecular recognition” This study found that hydrophilic carbon dots (Lys-CA-CDs) induced bovine serum albumin to form more wormlike fibrils, while inhibiting hen egg white lysozyme from forming hair-like fibrils.
11 citations
,
May 2023 in “Journal of Cancer Research and Clinical Oncology” This review discusses various applications of CRISPR-based tools in cancer research, emphasizing their potential for investigating microRNA functions and developing microRNA-based therapies, despite challenges like off-target effects and delivery issues in using CRISPR/Cas9.
May 2024 in “European Journal of Immunology” This review discusses the potential of targeting Coenzyme A metabolism to restore metabolic balance, reduce chronic inflammation, and enhance immune function, particularly by modulating Vitamin B5 pathways involved in Th17-mediated inflammation and CD8-dependent anti-tumor immunity.
21 citations
,
October 2010 in “Encyclopedia of Life Sciences” This article discusses the use of histoculture in cancer treatment, hair growth studies, and immune response research, but reports no new clinical results.
22 citations
,
April 1998 in “Dermatologic Clinics” This article reviews the therapeutic use of interferons and other cytokines in various viral, tumorous, and inflammatory diseases, discussing their biological effects and potential future applications without presenting new experimental results.
April 2024 in “Canadian Journal of Ophthalmology” The authors report that a 62-year-old woman with invasive conjunctival squamous cell carcinoma experienced complete remission two years after combining cemiplimab, retinoic acid, and IFNα-2b treatments, highlighting potential utility despite limited availability of IFNα-2b.
June 2026 in “Strathprints: The University of Strathclyde institutional repository (University of Strathclyde)” In this study, researchers found that inhibiting IKKα in patient-derived CCS tumour models reduces tumour viability, supporting the potential for topical IKKα inhibitors as a treatment for CCS.
March 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This publication presents a library of precision geometric medicines that reportedly kill harmful bacteria and fungi while sparing beneficial organisms, using a delivery system that targets pathogens specifically and avoids ecological harm.
7 citations
,
February 2014 in “Talanta” This study developed an advanced HPLC-ESI-ion trap MS(n) method for the structural identification of cyclosporin A analogs CyA and CyC and reported the first MS(n)-aided identification of a new CyA analog.
April 2026 in “International Journal of Drug Delivery Technology” This study found that Lactobacillus acidophilus cell-free supernatant caused significant cytotoxicity, reduced migratory ability, and induced apoptosis in cervical cancer cell lines, suggesting its potential as a non-toxic adjunct therapy for cervical cancer.
March 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This publication presents a library of geometric medicines designed to selectively target pathogenic bacteria and fungi with high precision while minimizing ecological harm, available for free on a non-commercial basis.
May 2024 in “bioRxiv (Cold Spring Harbor Laboratory)” This study found that hair with lower levels of keratin associated proteins reduced the foreign body response in mouse subcutaneous implant tests compared to hair with higher keratin levels.
15 citations
,
May 2010 in “International Journal of Cosmetic Science” This review discusses new developments in understanding the structure and properties of keratin fiber cell membrane complexes, without reporting new experimental results.
17 citations
,
January 2019 in “Journal of cancer” This study found that the medicinal formula YH0618 may reduce toxicity from the chemotherapy drug doxorubicin, improving side effects like hair loss and organ damage, while maintaining its anti-cancer effects.
40 citations
,
March 2019 in “Nature Communications” This study found that deleting Stim1 and Stim2 in mature T regulatory cells disrupts Ca 2+ signaling, preventing their differentiation and leading to severe autoimmune disorders in mice.
7 citations
,
January 2013 in “The journal of investigative dermatology/Journal of investigative dermatology” This study found that thymus transplantation in athymic mice resulted in T-cell-driven hair follicle depigmentation and loss, without multiorgan autoimmune disease, highlighting mechanisms of tissue-specific tolerance.
9 citations
,
July 2008 in “Oncology Reports” In this study, TC-1 cells, resembling stromal cells formed by epithelial-mesenchymal transition, significantly affected the behavior of normal human keratinocytes, supporting the role of stromal cells in tumor progression.
12 citations
,
September 2015 in “Drug Design Development and Therapy” This study found that the DOX derivative AD198 more effectively inhibited cell viability and induced apoptosis in canine cancer cell lines K9TCC and K9OSA compared to DOX in vitro.
7 citations
,
August 2025 in “European Journal of Endocrinology” The authors concluded that incorporating routine endocrinology consultations into transplant care could address CNI-related endocrine toxicities, but prospective studies are needed to assess the impact on graft and patient survival.
48 citations
,
August 2022 in “Chemical Biology & Drug Design” This review outlines computational strategies, including chemogenomics and drug repositioning, for coronavirus drug discovery and reports no new clinical findings; the authors highlight the advantages of these methods in rapidly identifying therapeutic candidates.
In this study, researchers analyzed over 5,000 T cells per sample using scRNA+TCR-seq technology and found that dual TCR Tregs are present in high proportions across various mouse tissues, showing unique TCR pairing patterns, V(D)J usage, and mRNA expression compared to single TCR Tregs.
July 2025 in “Ultrasound in Medicine & Biology” This study found that nanobubble-encapsulated diclofenac with ultrasound-targeted microbubble destruction (DNBs-UTMD) can enhance the anti-tumor efficacy of Doxil® by regulating the tumor immune microenvironment, improving drug uptake, and increasing T cell responses while reducing immune-suppressive cells in the process.
6 citations
,
March 2024 in “Saudi Pharmaceutical Journal” This study found that a nano-cubosome formulation co-loaded with capsaicin and thiocolchicoside enhanced bioavailability and showed promising analgesic and anti-inflammatory effects in rats, potentially benefiting gout management through improved transdermal delivery.
January 2025 in “Biomedical Reports” This case report describes the first successful use of telitacicept in treating a patient with systemic lupus erythematosus and a history of papillary thyroid carcinoma, suggesting its potential as a therapeutic option for such conditions.
18 citations
,
July 2024 in “Frontiers in Immunology” This review explores the complex relationships between ferroptosis, anastasis, and chemoresistance in cancer therapy, highlighting the potential of combining ferroptosis with immunotherapy to overcome resistance and improve personalized cancer treatments.